



***Attacking Devastating Diseases
With Breakthrough Science
Neuroscience***

**Martin Mackay, Ph.D.
Senior Vice President
Worldwide Research and Technology**



Neuroscience Vision

***We will Change Society
by Lifting the Burden of
Neuropsychiatric Disease***






Progress in Our Lifetimes

Strategy in Brief

- ◆ **Alzheimer's Disease – Fully Exploit Scientific Breakthroughs**
- ◆ **Cognition and ADHD – Increased Effort Builds Upon Internal Discoveries**
- ◆ **Bipolar Disorder and Schizophrenia – Advance Several Programs Into The Clinic**
- ◆ **Depression and Anxiety – Leverage New Science to Discover Novel Targets**
- ◆ **Sleep Quality – Mine the $\alpha 2\delta$ Advances**



A Substantial And Broad Program



Key Programs

- ◆ Lyrica for Fibromyalgia*
- ◆ S,S-Reboxetine for Neuropathic Pain*
- ◆ $\alpha 2\delta$ Platform*
- ◆ Alzheimer's Disease
 - RN1219 - Rinat
 - TTP488/TTP4000 - TransTech
- ◆ Schizophrenia
 - PDE-10 Inhibitor



*Indicates First-Time Disclosure By Pfizer Today



Lyrica


A Breakthrough for Fibromyalgia

Clinical Features

- ◆ Chronic, Widespread Pain
- ◆ Decreased Pain Threshold
- ◆ Several Co-Morbidities (e.g., Sleep, Fatigue, Anxiety)

High Medical Need


- ◆ Prevalent, Poorly Diagnosed, and Badly Managed Condition
- ◆ No Approved Medicines






New Data – Just Released

Lyrica (mg/day)



Sustained Efficacy in Fibromyalgia Patients






S,S-Reboxetine *Neuropathic Pain*

- ◆ **Chronic, Non-Malignant Pain Where the Central Nervous System is Malfunctioning**
- ◆ **S,S-Reboxetine is a Highly Selective Norepinephrine Reuptake Inhibitor (NRI)**
- ◆ **Controlled-Release Formulation for Once-Daily Administration**






Pain Relief in Treatment Failures





A Thriving $\alpha 2\delta$ Portfolio



◆ PD-332,334

◆ Lyrica



◆ PD-200,390



Neuroscience



◆ PD-299,685



Women's Health



◆ PF-293,765

◆ PF-2,393,296


◆ Lyrica



Pain



PD-332,334 Impressive Results in Anxiety



% of Patients Greater Than or Equal to 50% Reduction HAM-A



PD-200,390


A Breakthrough for Sleep Quality

- ◆ **Insomnia Impacts 50% of General Population**
- ◆ **10% of General Population Suffer from Poor Sleep Quality**
- ◆ **Program Covers Insomnia and Sleep Quality**





PD-200,390 Total Sleep Time





PD-200,390 Number of Awakenings

